Evidence map›Paper›PMID 36142688›Full record

ArticleInternational journal of molecular sciences2022

Biological Evaluation of 3-Azaspiro[Bicyclo[3.1.0]Hexane-2,5'-Pyrimidines] as Potential Antitumor Agents.

Stanislav V Shmakov, Diana K Latypova, Tatiana V Shmakova, Artem A Rubinshtein, Mark V Chukin, Sergei G Zhuravskii, Nickolay A Knyazev, Alexander V Stepakov, Michael M Galagudza, Vitali M Boitsov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Study of Cytotoxicity of Pyrrolo[3,4-International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Stanislav V ShmakovLaboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, 194021 Saint-Petersburg, Russia.
Diana K LatypovaLaboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, 194021 Saint-Petersburg, Russia.
Tatiana V ShmakovaInstitute of Experimental Medicine, Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, 194156 Saint-Petersburg, Russia.
Artem A RubinshteinScientific Research Center, Pavlov First Saint Petersburg State Medical University, 197022 Saint-Petersburg, Russia.ORCID 0000-0002-8493-5211
Mark V ChukinScientific Research Center, Pavlov First Saint Petersburg State Medical University, 197022 Saint-Petersburg, Russia.ORCID 0000-0003-2562-9342
Sergei G ZhuravskiiInstitute of Experimental Medicine, Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, 194156 Saint-Petersburg, Russia.
Nickolay A KnyazevInstitute of Cytology, Russian Academy of Sciences, 194064 Saint-Petersburg, Russia.
Alexander V StepakovDepartment of Chemistry, Saint-Petersburg State University, 199034 Saint-Petersburg, Russia.
Michael M GalagudzaInstitute of Experimental Medicine, Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, 194156 Saint-Petersburg, Russia.
Vitali M BoitsovLaboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, 194021 Saint-Petersburg, Russia.ORCID 0000-0002-4857-2046
First Pavlov State Medical University of St. Petersburg · RUSaint Petersburg Academic University · RUFederal Almazov North-West Medical Research Centre · RUInstitute of Cytology · RUSt Petersburg University · RU

Funding

Russian Science Foundation RSF 20-15-00332
6 · The paper itself

Abstract

A series of heterocyclic compounds containing spirofused barbiturate and 3-azabicyclo[3.1.0]hexane frameworks have been studied as potential antitumor agents. Antiproliferative activity of products was screened in human erythroleukemia (K562), T lymphocyte (Jurkat), and cervical carcinoma (HeLa) as well as mouse colon carcinoma (CT26) and African green monkey kidney epithelial (Vero) cell lines. The most effective among the screened compounds show IC

Indexed as

Antineoplastic AgentsCarcinomaActinsAnimalsApoptosisCell Line, TumorCell ProliferationChlorocebus aethiopsDrug Screening Assays, AntitumorHeLa CellsHexanesHumansMicePyrimidinesActinsAntineoplastic AgentsHexanesn-hexanePyrimidines3-azaspiro[bicyclo[3.1.0]hexane-2,5′-pyrimidines]alloxan-derived azomethine ylideantiproliferative activitycancer cell lines (K-562cell cyclecell deathcell motilityCT26cyclopropenesHeLain vitro and in vivo activityJurkatmorphological changes (cytoskeleton)Vero)

Identifiers

PMID36142688
PMCPMC9506420
OpenAlexW4296280764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.